Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

BURROUGHS WELLCOME INTRODUCING ACTIFED ALLERGY to the trade in December. The daytime/nighttime dosing regimen will be offered in one SKU in boxes with 24 daytime caplets (pseudoephedrine 30 mg) and eight nighttime caplets (pseudoephedrine 30 mg and diphenhydramine 25 mg). Packaging directions recommend that consumers take two tablets every four to six hours during the day and two nighttime caplets at bedtime. The product is intended to complement the company's existing day/night product, Actifed Sinus which was introduced in July 1992. Burroughs Wellcome said it is dedicating $ 6 mil. in 1994 to an advertising program that will feature the new product. The ad agency of record for the existing Actifed line is Now York City- based Backer Spielvogel Bates. Television ads featuring Actifed Allergy are expected to debut in March. The line extension also will be supported by a full- page, free-standing insert expected to reach 45 mil. consumers in Sunday newspapers on April 24. The FSI will feature a $ 1-off coupon. The company is also offering consumers $ 1 IRCs in March. Separately, Burroughs Wellcome expects to highlight its recently launched liquid cap, Sudafed Cold & Cough, in a co- promotion with Ricola cough drops during the 1993-1994 cold season. The marketing collaboration with Morris Plains, N.J.-based Ricola, Inc. will piggyback a 10-liquid-cap package of Sudafed Cold & Cough with a complimentary roll of Ricola cough drops.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts